Quantitative analysis of post-translational modifications in human serum transthyretin associated with familial amyloidotic polyneuropathy by targeted LC-MS and intact protein MS

Journal of Proteomics

Volumn 127, Issue , 2015, Pages 234-246

  Vilà Rico, Marta ^a   Colomé Calls, Núria ^b   Martín Castel, Luna ^b   Gay, Marina ^c   Azorín, Sebastián ^d   Vilaseca, Marta ^c   Planas, Antoni ^a   Canals, Francesc ^b  

^a INSTITUT QUÍMIC DE SARRIÀ   (Spain)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Absolute quantification; High resolution XIC quantification; Intact protein analysis; Post translational modifications; Targeted proteomics; Transthyretin

Indexed keywords

PREALBUMIN;

ARTICLE; CONTROLLED STUDY; FAMILIAL AMYLOID POLYNEUROPATHY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SULFONATION; AMINO ACID SUBSTITUTION; BLOOD; FEMALE; GENETICS; MALE; METABOLISM; MISSENSE MUTATION; PROCEDURES; PROTEIN PROCESSING;

AMINO ACID SUBSTITUTION; AMYLOID NEUROPATHIES, FAMILIAL; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MUTATION, MISSENSE; PREALBUMIN; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOMICS;

EID: 84944164987     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2015.04.016     Document Type: Article

References (38)

1. Raz A., Goodman D.S. The interaction of thyroxine with human plasma prealbumin and with the prealbumin-retinol binding protein complex. J Biol Chem 1969, 244(12):3230-3237.
2. Raz A., Shiratori T., Goodman D.S. Studies on the protein-protein and protein-ligand interactions involved in retinol transport in plasma. J Biol Chem 1970, 245(8):1903-1912.
3. Soprano D.R., Herbert J., Soprano K.J., Schon E.A., Goodman D.S. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. J Biol Chem 1985, 260(21):11793-11798.
4. Schreiber G., Aldred A.R., Jaworowski A., Nilsson C., Achen M.G., Segal M.B. Thyroxine transport from blood to brain via transthyretin synthesis in choroid plexus. Am J Physiol 1990, 258(2 Pt 2):R338-R345.
5. Westermark P., Sletten K., Johansson B., Cornwell G.G. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A 1990, 87(7):2843-2845.
6. Connors L.H., Lim A., Prokaeva T., Roskens V.A., Costello C.E. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003, 10(3):160-184.
7. Saraiva M.J. Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies. Expert Rev Mol Med 2002, 4(12):1-11.
8. Arsequell G., Planas A. Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands. Curr Med Chem 2012, 19(15):2343-2355.
9. Colon W., Kelly J.W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992, 31(36):8654-8660.
10. Quintas A., Saraiva M.J., Brito R.M. The tetrameric protein transthyretin dissociates to a non-native monomer in solution. A novel model for amyloidogenesis. J Biol Chem 1992, 274(46):32943-32949.
11. Quintas A., Vaz D.C., Cardoso I., Saraiva M.J., Brito R.M. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem 2001, 276(29):27207-27213.
12. Cardoso I., Goldsbury C.S., Muller S.A., Olivieri V., Wirtz S., Damas A.M., et al. Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils. J Biol Chem 2002, 317(5):683-695.
13. Hurshman A.R., White J.T., Powers E.T., Kelly J.W. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 2004, 43(23):7365-7381.
14. Sousa M.M., Cardoso I., Fernandes R., Guimarães A., Saraiva M.J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of non-fibrillar aggregates. Am J Pathol 2001, 159(6):1993-2000.
15. Sörgjerd K., Klingstedt T., Lindgren M., Kågedal K., Hammarström P. Prefibrillar transthyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in cell culture. Biochem Biophys Res Commun 2008, 377(4):1072-1078.
16. Buxbaum J., Anan I., Suhr O. Serum transthyretin levels in Swedish TTR V30M carriers. Amyloid 2010, 17(2):83-85.
17. Saraiva M.J., Costa P.P., Goodman D.S. Studies on plasma transthyretin (prealbumin) in familial amyloidotic polyneuropathy, Portuguese type. J Lab Clin Med 1983, 102(4):590-603.
18. Terazaki H., Ando Y., Suhr O., Ohlsson P.I., Obayashi K., Yamashita T., et al. Post-translational modification of transthyretin in plasma. Biochem Biophys Res Commun 1998, 249(1):26-30.
19. Altland K., Winter P., Sauerborn M.K. Electrically neutral microheterogeneity of human plasma transthyretin (prealbumin) detected by isoelectric focusing in urea gradients. Electrophoresis 1999, 20(7):1349-1364.
20. Poulsen K., Bahl J.M., Tanassi J.T., Simonsen A.H., Heegaard N.H. Characterization and stability of transthyretin isoforms in cerebrospinal fluid examined by immunoprecipitation and high-resolution mass spectrometry of intact protein. Methods 2012, 56(2):284-292.
21. Nakanishi T., Yoshioka M., Moriuchi K., Yamamoto D., Tsuji M., Takubo T. S-sulfonation of transthyretin is an important trigger step in the formation of transthyretin-related amyloid fibril. Biochim Biophys Acta 2010, 1804(7):1449-1456.
22. Kingsbury J.S., Klimtchuk E.S., Théberge R., Costello C.E., Connors L.H. Expression, purification, and in vitro cysteine-10 modification of native sequence recombinant human transthyretin. Protein Expr Purif 2007, 53(2):370-377.
23. Zhang Q., Kelly J.W. Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions. Biochemistry 2003, 42(29):8756-8761.
24. Hammarström P., Jiang X., Hurshman A.R., Powers E.T., Kelly J.W. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A 2002, 99(Suppl. 4):16427-16432.
25. Jiang X., Smith C.S., Petrassi H.M., Hammarström P., White J.T., Sacchettini J.C., et al. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 2001, 40(38):11442-11452.
26. Kishikawa M., Nakanishi T., Miyazaki A., Shimizu A. Enhanced amyloidogenicity of sulfonated transthyretin in vitro, a hypothetical etiology of senile amyloidosis. Amyloid 1999, 6(3):183-186.
27. Altland K., Winter P. Potential treatment of transthyretin-type amyloidoses by sulfite. Neurogenetics 1999, 2(3):183-188.
28. Bergquist J., Andersen O., Westman A. Rapid method to characterize mutations in transthyretin in cerebrospinal fluid from familial amyloidotic polyneuropathy patients by use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2000, 46(9):1293-1300.
29. Trenchevska O., Kamcheva E., Nedelkov D. Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants. Proteomics 2011, 11(18):3633-3641.
30. da Costa G., Gomes R., Correia C.F., Freire A., Monteiro E., Martins A., et al. Identification and quantitative analysis of human transthyretin variants in human serum by Fourier transform ion-cycloton resonance mass spectrometry. Amyloid 2009, 16(4):201-207.
31. Ribeiro-Silva C., Gilberto S., Gomes R.A., Mateus É., Monteiro E., Barroso E., et al. The relative amounts of plasma transthyretin forms in familial transthyretin amyloidosis: a quantitative analysis by Fourier transform ion-cyclotron resonance mass spectrometry. Amyloid 2011, 18(4):191-199.
32. Kishikawa M., Nakanishi T., Miyazaki A., Shimizu A., Nakazato M., Kangawa K., et al. Simple detection of abnormal serum transthyretin from patients with familial amyloidotic polyneuropathy by high-performance liquid chromatography/electrospray ionization mass spectrometry using material precipitated with specific antiserum. J Mass Spectrom 1996, 31(1):112-114.
33. Ando Y., Ohlsson P.I., Suhr O., Nyhlin N., Yamashita T., Holmgren G., et al. A new simple and rapid screening method for variant transthyretin-related amyloidosis. Biochem Biophys Res Commun 1996, 228(2):480-483.
34. Ando Y., Suhr O., Yamashita T., Ohlsson P.I., Holmgreen G., Obayashi K., et al. Detection of different forms of variant transthyretin (Met30) in cerebrospinal fluid. Neurosci Lett 1997, 238(3):123-126.
35. Suhr O.B., Svendsen I.H., Ohlsson P.I., Lendoire J., Trigo P., Tashima K., et al. Impact of age and amyloidosis on thiol conjugation of transthyretin in hereditary transthyretin amyloidosis. Amyloid 1999, 6(3):187-191.
36. Lim A., Prokaeva T., McComb M.E., Connors L.H., Skinner M., Costello C.E. Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis. Protein Sci 2003, 12(8):1775-1785.
37. Dolado I., Nieto J., Saraiva M.J., Arsequell G., Valencia G., Planas A. Kinetic assay for high-throughput screening of in vitro transthyretin amyloid fibrillogenesis inhibitors. J Comb Chem 2005, 7(2):246-252.
38. Ritchie R.F., Palomaki G.E., Neveux L.M., Navolotskaia O., Ledue T.B., Craig W.Y. Reference distributions for the negative acute-phase serum proteins, albumin, transferring and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 1999, 13(6):273-279.